Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

NCT04143594 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

183

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1-infection

Interventions

DRUG: Oral Lenacapavir
DRUG: F/TAF
DRUG: Subcutaneous Lenacapavir
DRUG: TAF
DRUG: BIC
DRUG: B/F/TAF

Sponsor

Gilead Sciences